Clinical and Neurologic Outcomes in Acetaminophen-Induced Acute Liver Failure: A 21-Year Multicenter Cohort Study
Andrew J. MacDonald, Bilal Hameed(University of California, San Francisco), James Hanje(The Ohio State University), Kathleen M. Nilles(Georgetown University), Jodi Olson, Brendan M. McGuire(University of Alabama at Birmingham), Natalie Murray(Institute of Genetics), Adrian Reuben(Medical University of South Carolina), Andrés T. Blei(Northwestern University), K. Rajender Reddy(Hospital of the University of Pennsylvania), Tarek Hassanein, Timothy M. McCashland(University of Nebraska–Lincoln), Constantine Karvellas(University of Alberta), R. Todd Stravitz(Virginia Commonwealth University), Robert J. Fontana(University of Michigan), Michael L. Schilsky(Yale University), William M. Lee(The University of Texas Southwestern Medical Center), Babak J. Orandi(University of Alabama at Birmingham), Edwin Harrison, A. Obaid S. Shaikh, Lorenzo Rossaro(University of California Davis Medical Center), Oren K. Fix(Swedish Medical Center), Robert S. Brown(Cornell University), Anne M. Larson(University of Washington), Daniel Ganger(Northwestern University), Santiago J. Muñoz(Einstein Medical Center Philadelphia), Alastair D. Smith(Duke Medical Center), J. Eileen Hay(Mayo Clinic in Arizona), Steven Han(The Ohio State University), Atif Zaman, Iris Liou(University of Washington), Raj Satyanarayana(Jacksonville College), Ram Subramanian(Emory University), Jaime L. Speiser(Wake Forest University), Raymond T. Chung, Jeffrey S. Crippin(Washington University in St. Louis)
Cited by 39
Related Papers
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Liver biopsy†
|Hepatology|2008|1.9k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Connecting copper and cancer: from transition metal signalling to metalloplasia
|Nature reviews. Cancer|2021|1.3k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k